Raia Drogasil (OTCMKTS:RADLY) Sees Strong Trading Volume – What’s Next?

Raia Drogasil S.A. (OTCMKTS:RADLYGet Free Report) saw an uptick in trading volume on Tuesday . Approximately 395,106 shares changed hands during trading, an increase of 521% from the previous session’s volume of 63,579 shares.The stock last traded at $3.7326 and had previously closed at $3.7490.

Raia Drogasil Trading Down 0.6%

The company’s 50 day moving average price is $3.67 and its two-hundred day moving average price is $3.99. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.41 and a quick ratio of 0.58.

Raia Drogasil (OTCMKTS:RADLYGet Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.05 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.05. Raia Drogasil had a net margin of 2.97% and a return on equity of 18.20%. The company had revenue of $2.17 billion during the quarter, compared to analysts’ expectations of $2.32 billion. On average, research analysts anticipate that Raia Drogasil S.A. will post 0.17 earnings per share for the current year.

About Raia Drogasil

(Get Free Report)

Raia Drogasil, now operating under the brand name RD Saúde, is a Brazilian healthcare and pharmacy retail company. It operates a nationwide network of pharmacies that sells prescription and over-the-counter medicines, personal-care products, cosmetics, health and wellness items, and convenience products.

The company also provides digital shopping and delivery services through its online channels, supporting customers with medication and health-related purchases. Its operations combine physical stores with e-commerce and other healthcare-related services, serving consumers throughout Brazil.

RD Saúde was formed in 2011 through the merger of Drogasil and Droga Raia, two pharmacy chains with roots dating back to the early twentieth century.

See Also

Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.